28/10/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with masitinib Download PDF Post navigationPreviousPrevious post:AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSNextNext post:Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CETRelated PostsSummary of the webcast held on January 28, 2025January 29, 2025Summary of the webcast held on December 16, 2024December 17, 2024AB Science webcast of December 16, 2024December 16, 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CETDecember 11, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024Revenues for the first half of 2024 and update on AB Science’s activitiesOctober 10, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024
